2015
Stroke Issue 2015
Krumholz HM. Stroke Issue 2015. Circulation Cardiovascular Quality And Outcomes 2015, 8: s65. PMID: 26515210, PMCID: PMC6481163, DOI: 10.1161/circoutcomes.115.002345.Peer-Reviewed Original Research
2005
The generalizability of observational data to elderly patients was dependent on the research question in a systematic review
Gross CP, Garg PP, Krumholz HM. The generalizability of observational data to elderly patients was dependent on the research question in a systematic review. Journal Of Clinical Epidemiology 2005, 58: 130-137. PMID: 15680745, DOI: 10.1016/j.jclinepi.2004.10.001.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectIntracranial hemorrhageSystematic reviewBeta-blocker useElderly patientsAngiography useCommunity patientsAtrial fibrillationRisk factorsObservational studyOutcome measuresRCT dataPresentation delayGlobal UtilizationT-PAPatientsSimilar predictorsTreatment variationStudy questionsCCP dataGUSTOHemorrhageReviewFibrillationAbsolute rate
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2003
Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study
Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, Every NR. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. American Heart Journal 2003, 146: 839-847. PMID: 14597933, DOI: 10.1016/s0002-8703(03)00408-3.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectRandomized trialsExclusion criteriaEligibility criteriaMortality rateClinical practiceKillip class III/IVClass III/IVOccluded Coronary Arteries (GUSTO-I) trialCoronary Arteries trialHospital mortality rateMyocardial infarction careTrial eligibility criteriaHigh mortality rateRetrospective registryBaseline characteristicsClinical characteristicsElderly patientsOlder patientsCCP patientsClinical presentationClinical eventsMyocardial infarctionHealthy cohortHospital characteristics
2002
Thrombolysis for Acute Stroke in Routine Clinical Practice
Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for Acute Stroke in Routine Clinical Practice. JAMA Internal Medicine 2002, 162: 1994-2001. PMID: 12230423, DOI: 10.1001/archinte.162.17.1994.Peer-Reviewed Original ResearchConceptsMajor protocol deviationsRoutine clinical practiceConnecticut cohortProtocol deviationsHospital mortalityAcute strokeThrombolytic therapyClinical practiceExtracranial hemorrhageCommunity-based patientsMinor protocol deviationsHigh rateIntravenous thrombolysisAdverse eventsRetrospective cohortHemorrhage ratePatient outcomesConnecticut hospitalsPatientsThrombolysisNeurological disordersCohortExperienced cliniciansStudy settingTherapy
2000
Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: Analysis of the Cooperative Cardiovascular Project
Berger A, Radford M, Krumholz H. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: Analysis of the Cooperative Cardiovascular Project. American Heart Journal 2000, 139: 985-992. PMID: 10827378, DOI: 10.1067/mhj.2000.105703.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnistreplaseElectrocardiographyFemaleHumansMaleMyocardial InfarctionPatient AdmissionPlasminogen ActivatorsQuality Indicators, Health CareRetrospective StudiesRisk FactorsStreptokinaseSurvival RateThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment FailureUnited StatesConceptsAcute myocardial infarctionHospital arrivalElderly patientsMortality rateMyocardial infarctionCardiology/American Heart Association guidelinesAmerican Heart Association guidelinesAdministration of thrombolysisHistory of hypertensionHeart Association guidelinesCooperative Cardiovascular Project databaseCooperative Cardiovascular ProjectCardiac catheterization laboratoryReperfusion therapyClinical characteristicsHeart failureST elevationThrombolytic therapyAssociation guidelinesHospital characteristicsCatheterization laboratoryAmerican CollegeThrombolysisPatientsRapid treatment
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchMeSH KeywordsAgedCost-Benefit AnalysisDecision Support TechniquesHumansModels, EconomicMyocardial InfarctionQuality-Adjusted Life YearsStreptokinaseThrombolytic TherapyTissue Plasminogen ActivatorConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage